CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
People›
John W. Childs
AddedFeb 19, 2024
UpdatedJun 28, 2026
John W. Childs

John W. Childs

Board Member, Biohaven

John W. Childs's Career

Biohaven

Biohaven

$12.4BNew Haven, CT, US
Board Member· Board

Leadership at Biohaven

Michael HeffernanMichael HeffernanBoard Member
Rob BermanRob BermanFounder
Vlad CoricVlad CoricBoard Member

Similar to Biohaven

Harmony BiosciencesHarmony BiosciencesPlymouth Meeting, PA, USPharmaceuticalsest. 2017Harmony BiosciencesPlymouth Meeting, PA, US · est. 2017

Harmony Biosciences: Innovating therapies for rare neurological disorders in the U.S.

Public · $1.2B200
New Haven PharmaceuticalsNew Haven PharmaceuticalsNorth Haven, CT, USDrugs, Pharmaceuticalsest. 2008New Haven PharmaceuticalsNorth Haven, CT, US · est. 2008

New Haven Pharmaceuticals, Inc. develops and markets specialty, controlled-release prescription drugs globally.

Public · $27.2M11
TrevenaTrevenaKing of Prussia, PA, USPharmaceuticalsest. 2007TrevenaKing of Prussia, PA, US · est. 2007

Trevena: A biopharmaceutical firm innovating novel CNS disorder treatments.

Public · $473.7M35
Ovid TherapeuticsOvid TherapeuticsNew York City, NY, USTherapeuticsest. 2014Ovid TherapeuticsNew York City, NY, US · est. 2014

NY-based Ovid Therapeutics Inc. develops medicines for rare neurological disorders.

Public · $184.1M40

John W. Childs's Co-Investors

Gregory BaileyGregory BaileyCo-invested · Bristol Myers Squibb Post IPO Equity · 2 dealsCarl IcahnCarl IcahnCo-invested · Bristol Myers Squibb Post IPO Equity

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

John W. Childs's Investments

2 investments since 2016

1 operating · 1 acquired

Investments view
Group by

2017

1
  • Bristol Myers SquibbBristol Myers Squibb
    Post IPO Equity · February 2017$80M
    Post IPO Equity · February 2017

2016

1
  • BiohavenBiohaven
    Series Unknown · November 2016$80M
    Series Unknown · November 2016

People Similar to John W. Childs

Karen BernsteinKaren BernsteinBoard Member · Ovid TherapeuticsJoerg MoellerJoerg MoellerBoard Member · Secura BioMichael PaviaMichael PaviaBoard Member · Azevan PharmaceuticalsViren GroverViren GroverBoard Member · Pinnacle BiologicsBrian KennedyBrian KennedyFounder · Aeovian PharmaceuticalsKim A HeidenreichKim A HeidenreichFounder · Bioscience Pharma PartnersLynne PowellLynne PowellBoard Member · Biora Therapeutics